7,625.56

+45.49

+0.60%

52,281.96

+511.65

+0.99%

25,653.23

+216.24

+0.85%

2,828.87

+17.02

+0.61%

4.9000

-0.0290

-0.59%

19.02

-0.40

-2.06%

3,970.50

+71.60

+1.84%

77,585.46

-339.20

-0.44%

Crude Oil Dec 26

97.40

-6.72

-6.45%

US Private Equity

10,850.63

-82.20

-0.75%

NasdaqCM - Nasdaq Real Time Price USD

Exicure, Inc. (XCUR)

1.0450 +0.0350 (+3.47%)

As of 9:30:02 AM EST. Market Open.

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders’ Equity Requirement

GlobeNewswire 1mo ago

XCUR
+3.47%
Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance

GlobeNewswire 2mo ago

XCUR
+3.47%
Exicure Announces Board and Committee Changes

GlobeNewswire 4mo ago

XCUR
+3.47%
^IXIC
Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement

GlobeNewswire 4mo ago

XCUR
+3.47%
^IXIC
Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

GlobeNewswire 4mo ago

XCUR
+3.47%
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

GlobeNewswire 6mo ago

XCUR
+3.47%
179530.KQ
Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

GlobeNewswire 6mo ago

XCUR
+3.47%
Exicure, Inc. Reports Full Year 2025 Financial Results

GlobeNewswire 7mo ago

XCUR
+3.47%
Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant

GlobeNewswire 8mo ago

XCUR
+3.47%
Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings

GlobeNewswire 9mo ago

XCUR
+3.47%
Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting

GlobeNewswire 10mo ago

XCUR
+3.47%

Performance Overview

Return	XCUR	S&P 500 (^GSPC)
YTD	-81.37%	+10.73%
1-Year	-77.25%	+11.11%
3-Year	-67.42%	+81.91%

Mobilize your Website

View Site in Mobile | Classic

Share by: